Disseminated Varicella Infection Due to the Vaccine Strain of Varicella-Zoster Virus, in a Patient with a Novel Deficiency in Natural Killer T Cells

Journal of Infectious Diseases

Volumn 188, Issue 7, 2003, Pages 948-953

  Levy, Ofer ^a,f   Orange, Jordan S ^a   Hibberd, Patricia ^a   Steinberg, Sharon ^d   LaRussa, Phillip ^d   Weinberg, Adriana ^e   Wilson, S Brian ^c   Shaulov, Angela ^a   Fleisher, Gary ^b   Geha, Raif S ^a   Bonilla, Francisco A ^a   Exley, Mark ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Columbia University ^*  (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

ARTICLE; ASPIRATION; CASE REPORT; CLINICAL FEATURE; DEATH; DISEASE COURSE; ENDOTRACHEAL TUBE; FEMALE; HERPES ZOSTER; HOST RESISTANCE; HUMAN; LABORATORY TEST; LUNG LAVAGE; NATURAL KILLER CELL; PRIORITY JOURNAL; RASH; RESPIRATORY DISTRESS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; TREATMENT OUTCOME; VACCINATION REACTION; VARICELLA ZOSTER VIRUS; VIRUS ISOLATION;

ANTIGENS, VIRAL; CHICKENPOX VACCINE; CHILD; DNA, VIRAL; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNE SYSTEM; IMMUNOCOMPROMISED HOST; KILLER CELLS, NATURAL; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; VACCINATION; VACCINES, ATTENUATED;

EID: 0142074335     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/378503     Document Type: Article

References (23)

1. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287:606-11.
2. White CJ. Varicella-zoster virus vaccine. Clin Infect Dis 1997; 24: 753-63.
3. Kramer JM, LaRussa P, Tsai WC, et al. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 2001; 108:E39.
4. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2001; 19:916-23.
5. Ghaffar F, Carrick K, Rogers BB, Margraf LR, Krisher K, Ramilo O. Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency. Pediatr Infect Dis J 2000; 19:764-6.
6. Arvin AM. Varicella-zoster virus: molecular virology and virus-host interactions. Curr Opin Microbiol 2001; 4:442-9.
7. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 2002; 4:1545-58.
8. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CDI recognition by mouse NK1+ T lymphocytes. Science 1995; 268:863-5.
9. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Vα24+CD4-CD8- T cells. J Exp Med 1997; 186:109-20.
10. Matsuda JL, Kronenberg M. Presentation of self and microbial lipids by CD1 molecules. Curr Opin Immunol 2001; 13:19-25.
11. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science 1997; 278:1626-9.
12. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001; 13:458-64.
13. Johnson TR, Hong S, Van Kaer L, Koezuka Y, Graham BS. NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 2002; 76: 4294-303.
14. Grubor-Bauk B, Simmons A, Mayrhofer G, Speck PG. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant V alpha 14-J alpha 281 TCR. J Immunol 2003; 170:1430-4.
15. Exley MA, Bigley NJ, Cheng O, et al. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J Leukoc Biol 2001; 69:713-8. (erratum: J Leukoc Biol 2001; 70:340)
16. LaRussa P, Steinberg S, Arvin A, et al. Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world. J Infect Dis 1998; 178(Suppl 1):S64-6.
17. Weinberg A, Wohl Da, Brown DG, et al. Effect of cryopreservation on measurement of cytomegalovirus-specific cellular immune responses in HIV-infected patients. J Acquir Immune Defic Syndr 2000; 25:109-14.
18. Orange JS, Brodeur SR, Jain A, et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest 2002; 109:1501-9.
19. Tahir SM, Cheng O, Shaulov A, et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001; 167:4046-50.
20. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000;21:573-83.
21. Reynolds DW, Dean PH, Pass RF, Alford CA. Specific cell-mediated immunity in children with congenital and neonatal cytomegalovirus infection and their mothers. J Infect Dis 1979; 140:493-9.
22. Cauda R, Prasthofer EF, Grossi CE, Whitley RJ, Pass RF. Congenital cytomegalovirus: immunological alterations. J Med Virol 1987; 23:41-9.
23. Hobbs JA, Cho S, Roberts TJ, et al. Selective loss of natural killer T cells by apoptosis following infection with lymphocytic choriomeningitis virus. J Virol 2001; 75:10746-54.